Transgenic expression of cyclooxygenase-2 in mouse intestine epithelium is insufficient to initiate tumorigenesis but promotes tumor progression

This publication has 41 references indexed in Scilit:

• COX-2 in play at the AHA and the FDA
  Trends in Pharmacological Sciences, 2007
• Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of COX-2
  New England Journal of Medicine, 2007
• Cyclooxygenase-2 transactivates the epidermal growth factor receptor through specific E-prostanoid receptors and Tumor Necrosis Factor-α converting enzyme
  Cellular Signalling, 2007
• Protection against Fas-induced liver apoptosis in transgenic mice expressing cyclooxygenase 2 in hepatocytes
  Hepatology, 2007
• EP2, a receptor for PGE2, regulates tumor angiogenesis through direct effects on endothelial cell motility and survival
  Oncogene, 2006
• Azoxymethane Is a Genetic Background-Dependent Colorectal Tumor Initiator and Promoter in Mice: Effects of Dose, Route, and Diet
  Toxicological Sciences, 2005
• The Prostaglandin E2 Receptor EP2 Is Required for Cyclooxygenase 2–Mediated Mammary Hyperplasia
  Cancer Research, 2005
• Cyclooxygenase-2 and Epidermal Growth Factor Receptor: Pharmacologic Targets for Chemoprevention
  Journal of Clinical Oncology, 2005
• Prostaglandin E2 Synergistically Enhances Receptor Tyrosine Kinase-dependent Signaling System in Colon Cancer Cells
  Journal of Biological Chemistry, 2004
• Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2.
  Gut, 1994